PT99086A - Processo para a preparacao de uma composicao contendo base efedrina e salicilato de alquilo para a libertacao da base efedrina sob a forma de vapor - Google Patents
Processo para a preparacao de uma composicao contendo base efedrina e salicilato de alquilo para a libertacao da base efedrina sob a forma de vapor Download PDFInfo
- Publication number
- PT99086A PT99086A PT99086A PT9908691A PT99086A PT 99086 A PT99086 A PT 99086A PT 99086 A PT99086 A PT 99086A PT 9908691 A PT9908691 A PT 9908691A PT 99086 A PT99086 A PT 99086A
- Authority
- PT
- Portugal
- Prior art keywords
- weight
- salicylate
- ephedrine
- base
- process according
- Prior art date
Links
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims description 177
- 239000000203 mixture Substances 0.000 claims description 102
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 91
- 229960002179 ephedrine Drugs 0.000 claims description 89
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims description 38
- -1 alkyl salicylate Chemical compound 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 32
- 229960001860 salicylate Drugs 0.000 claims description 31
- 229960001047 methyl salicylate Drugs 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 13
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 12
- 241000723346 Cinnamomum camphora Species 0.000 claims description 12
- 229930008380 camphor Natural products 0.000 claims description 12
- 229960000846 camphor Drugs 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 10
- 229940041616 menthol Drugs 0.000 claims description 10
- GYCKQBWUSACYIF-UHFFFAOYSA-N Ethyl salicylate Chemical compound CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 9
- 229940062909 amyl salicylate Drugs 0.000 claims description 9
- NYNCZOLNVTXTTP-UHFFFAOYSA-N ethyl 2-(1,3-dioxoisoindol-2-yl)acetate Chemical compound C1=CC=C2C(=O)N(CC(=O)OCC)C(=O)C2=C1 NYNCZOLNVTXTTP-UHFFFAOYSA-N 0.000 claims description 9
- 229940005667 ethyl salicylate Drugs 0.000 claims description 9
- 150000001491 aromatic compounds Chemical class 0.000 claims description 8
- 235000009508 confectionery Nutrition 0.000 claims description 8
- 239000003921 oil Substances 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 210000002345 respiratory system Anatomy 0.000 claims description 6
- 239000000341 volatile oil Substances 0.000 claims description 5
- 210000002850 nasal mucosa Anatomy 0.000 claims description 4
- 239000002480 mineral oil Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000010672 sassafras oil Substances 0.000 claims description 3
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 2
- 235000011613 Pinus brutia Nutrition 0.000 claims description 2
- 241000018646 Pinus brutia Species 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000010642 eucalyptus oil Substances 0.000 claims description 2
- 229940044949 eucalyptus oil Drugs 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 20
- 125000003118 aryl group Chemical group 0.000 description 19
- 239000000243 solution Substances 0.000 description 17
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 14
- 239000000463 material Substances 0.000 description 11
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 229940112822 chewing gum Drugs 0.000 description 8
- 235000015218 chewing gum Nutrition 0.000 description 8
- 239000006196 drop Substances 0.000 description 8
- 239000005844 Thymol Substances 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 229960000790 thymol Drugs 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000010926 purge Methods 0.000 description 5
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000004264 Petrolatum Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 210000001331 nose Anatomy 0.000 description 4
- 229940066842 petrolatum Drugs 0.000 description 4
- 235000019271 petrolatum Nutrition 0.000 description 4
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical class CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 4
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 3
- 206010028735 Nasal congestion Diseases 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000779819 Syncarpia glomulifera Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 229960001985 dextromethorphan Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 239000007923 nasal drop Substances 0.000 description 3
- 229940100662 nasal drops Drugs 0.000 description 3
- 239000007922 nasal spray Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229960003908 pseudoephedrine Drugs 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000009834 vaporization Methods 0.000 description 3
- 230000008016 vaporization Effects 0.000 description 3
- 238000009423 ventilation Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000010627 cedar oil Substances 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000012808 vapor phase Substances 0.000 description 2
- CAVQBDOACNULDN-KHFUBBAMSA-N (1r,2s)-2-(methylamino)-1-phenylpropan-1-ol;sulfuric acid Chemical compound OS(O)(=O)=O.CN[C@@H](C)[C@H](O)C1=CC=CC=C1.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 CAVQBDOACNULDN-KHFUBBAMSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- KZYJXZMFIHHEML-UHFFFAOYSA-N 1-chlorohexadecane;pyridine Chemical compound C1=CC=NC=C1.CCCCCCCCCCCCCCCCCl KZYJXZMFIHHEML-UHFFFAOYSA-N 0.000 description 1
- TWADJGWUKGOPFG-UHFFFAOYSA-N 2-methoxy-5-methyl-1,3-diphenylbenzene Chemical compound COC1=C(C=2C=CC=CC=2)C=C(C)C=C1C1=CC=CC=C1 TWADJGWUKGOPFG-UHFFFAOYSA-N 0.000 description 1
- WWJLCYHYLZZXBE-UHFFFAOYSA-N 5-chloro-1,3-dihydroindol-2-one Chemical compound ClC1=CC=C2NC(=O)CC2=C1 WWJLCYHYLZZXBE-UHFFFAOYSA-N 0.000 description 1
- 101100065878 Caenorhabditis elegans sec-10 gene Proteins 0.000 description 1
- 241001630921 Chlorida Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- KGEKLUUHTZCSIP-UHFFFAOYSA-N Isobornyl acetate Natural products C1CC2(C)C(OC(=O)C)CC1C2(C)C KGEKLUUHTZCSIP-UHFFFAOYSA-N 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- FMCGSUUBYTWNDP-UHFFFAOYSA-N N-Methylephedrine Natural products CN(C)C(C)C(O)C1=CC=CC=C1 FMCGSUUBYTWNDP-UHFFFAOYSA-N 0.000 description 1
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
- 208000026344 Nasal disease Diseases 0.000 description 1
- 208000030880 Nose disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000009334 Singa Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000001940 [(1R,4S,6R)-1,7,7-trimethyl-6-bicyclo[2.2.1]heptanyl] acetate Substances 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229960002534 ephedrine hydrochloride Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000002035 hexane extract Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229940025704 inhalant product Drugs 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 1
- MYWUZJCMWCOHBA-SECBINFHSA-N levmetamfetamine Chemical compound CN[C@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-SECBINFHSA-N 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002221 methylephedrine Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012184 mineral wax Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 230000002911 mydriatic effect Effects 0.000 description 1
- 239000001627 myristica fragrans houtt. fruit oil Substances 0.000 description 1
- MYWUZJCMWCOHBA-UHFFFAOYSA-N n-methyl-1-phenylpropan-2-amine Chemical compound CNC(C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-UHFFFAOYSA-N 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 239000000133 nasal decongestant Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000014594 pastries Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000001739 pinus spp. Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000002693 spinal anesthesia Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229940036248 turpentine Drugs 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 239000006200 vaporizer Substances 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/590,646 US5175152A (en) | 1990-09-28 | 1990-09-28 | Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT99086A true PT99086A (pt) | 1992-08-31 |
Family
ID=24363071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT99086A PT99086A (pt) | 1990-09-28 | 1991-09-26 | Processo para a preparacao de uma composicao contendo base efedrina e salicilato de alquilo para a libertacao da base efedrina sob a forma de vapor |
Country Status (11)
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5853768A (en) * | 1995-03-01 | 1998-12-29 | Altadonna; James | Topical preparation and method for pain relief |
| US5785988A (en) * | 1996-05-10 | 1998-07-28 | Fust; Charles A. | Composition for freshening nostrils and sinus cavities |
| US6344210B2 (en) | 1996-05-10 | 2002-02-05 | Charles A. Fust | Composition for freshening nostrils and sinus cavities |
| US6769428B2 (en) * | 1997-01-29 | 2004-08-03 | Peter J. Cronk | Adhesively applied external nasal strips and dilators containing medications and fragrances |
| US6244265B1 (en) | 1997-01-29 | 2001-06-12 | Peter J. Cronk | Adhesively applied external nasal strips and dilators containing medications and fragrances |
| US20060029653A1 (en) | 1997-01-29 | 2006-02-09 | Cronk Peter J | Therapeutic delivery system |
| US5706800A (en) | 1997-01-29 | 1998-01-13 | Cronk; Peter J. | Medicated nasal dilator |
| US5948414A (en) * | 1998-03-24 | 1999-09-07 | Nouveau Technologies, Inc. | Herbal based nasal spray |
| US7150888B1 (en) | 2000-04-03 | 2006-12-19 | Inhalation, Inc. | Methods and apparatus to prevent colds, influenzaes, tuberculosis and opportunistic infections of the human respiratory system |
| US7048953B2 (en) * | 2000-04-03 | 2006-05-23 | Inhalation, Inc. | Methods and apparatus to prevent, treat and cure infections of the human respiratory system by pathogens causing severe acute respiratory syndrome (SARS) |
| US6776778B2 (en) * | 2000-12-18 | 2004-08-17 | Allen L. Prince | Nasal douche |
| WO2002094216A2 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of stimulants through an inhalation route |
| US7585493B2 (en) | 2001-05-24 | 2009-09-08 | Alexza Pharmaceuticals, Inc. | Thin-film drug delivery article and method of use |
| US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
| US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
| JP2005503425A (ja) | 2001-05-24 | 2005-02-03 | アレックザ モレキュラー デリヴァリー コーポレイション | 所定の吸入ルートによる薬剤エステルの送出 |
| US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
| US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
| JP2005535581A (ja) | 2002-05-02 | 2005-11-24 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 肺感染の拡大を制限する処方物 |
| US20050220720A1 (en) * | 2002-05-02 | 2005-10-06 | David Edwards | Formulations limiting spread of pulmonary infections |
| US7138394B2 (en) * | 2002-09-27 | 2006-11-21 | Alpharx Inc. | Vehicle for topical delivery of anti-inflammatory compounds |
| WO2004104492A2 (en) | 2003-05-21 | 2004-12-02 | Alexza Pharmaceuticals, Inc. | Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same |
| US20050207983A1 (en) * | 2004-03-05 | 2005-09-22 | Pulmatrix, Inc. | Formulations decreasing particle exhalation |
| US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
| US20060019987A1 (en) * | 2004-07-23 | 2006-01-26 | Fust Charles A | Methods and compositions for inhibiting, destroying, and/or inactivating viruses |
| AU2004322756B2 (en) | 2004-08-12 | 2011-04-14 | Alexza Pharmaceuticals, Inc. | Aerosol drug delivery device incorporating percussively activated heat packages |
| JP2008540680A (ja) * | 2005-05-18 | 2008-11-20 | プルマトリックス インコーポレイテッド | 粘膜内壁の生物物理学的な性質を変化させる製剤 |
| MX2009002195A (es) | 2006-08-30 | 2009-05-28 | David William Smith | Metodo para impartir una rigidez mono-axial o multi-axial a materiales extruidos y productos que resultan de los mismos. |
| US20080216828A1 (en) | 2007-03-09 | 2008-09-11 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
| WO2009047779A2 (en) * | 2007-06-20 | 2009-04-16 | Nikki Nikhilesh Singh | Composition containing fentanyl base aromatic oils and alkyl salicylate for the delivery of fentanyl base in vapour form |
| JP5877201B2 (ja) | 2010-08-30 | 2016-03-02 | パルマトリックス，インコーポレイテッド | 肺疾患を治療するための乾燥粉末製剤および方法 |
| US20130164338A1 (en) | 2010-08-30 | 2013-06-27 | Pulmatrix, Inc. | Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder |
| RU2017144619A (ru) | 2010-09-29 | 2019-02-20 | Пулмэтрикс, Инк. | Катионы одновалентных металлов сухих порошков для ингаляций |
| WO2012050945A1 (en) | 2010-09-29 | 2012-04-19 | Pulmatrix, Inc. | Cationic dry powders |
| HK1204989A1 (en) | 2012-02-29 | 2015-12-11 | Pulmatrix Operating Company, Inc. | Inhalable dry powders |
| AU2014248455B2 (en) | 2013-04-01 | 2018-12-06 | Pulmatrix Operating Company, Inc. | Tiotropium dry powders |
| US12214118B2 (en) | 2018-02-02 | 2025-02-04 | Alexza Pharmaceuticals, Inc. | Electrical condensation aerosol device |
| PL3897537T3 (pl) | 2018-12-18 | 2025-03-24 | The Procter & Gamble Company | Kompozycja do pielęgnacji osobistej o zwiększonym uwalnianiu oparów |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2196322A (en) * | 1937-12-04 | 1940-04-09 | Squibb & Sons Inc | Pharmaceutical |
| US2785103A (en) * | 1953-12-31 | 1957-03-12 | Abbott Lab | L-desoxyephedrine inhalant preparation |
| BE555319A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1956-03-21 | 1900-01-01 | ||
| US3236729A (en) * | 1961-08-03 | 1966-02-22 | Richardson Merrell Inc | Control of nasal congestion |
| US3138526A (en) * | 1962-11-06 | 1964-06-23 | Hoffmann La Roche | Compositions for treating bronchospastic disorders comprising theophylline, ephedrine, and 7-chloro-2-methylamino-5-phenyl-3h-1, 4-benzodiazepine-4-oxide |
| US3467754A (en) * | 1966-08-10 | 1969-09-16 | Mead Johnson & Co | Bronchodilator expectorant elixir |
| US3639622A (en) * | 1968-11-22 | 1972-02-01 | Geigy Chem Corp | Vasoconstricting and bronchodilating compositions and methods utilizing gallic acid and alkyl gallates |
| DD99927A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1972-10-23 | 1973-09-05 | ||
| AU520987B2 (en) * | 1978-05-08 | 1982-03-11 | Victor Alexander Garten | Anti-arthritic preparation |
| US4291015A (en) * | 1979-08-14 | 1981-09-22 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing a vasodilator |
| JPS5829706A (ja) * | 1981-08-14 | 1983-02-22 | Toko Yakuhin Kogyo Kk | 消炎鎮痛外用剤 |
| US4486436A (en) * | 1982-07-22 | 1984-12-04 | Analgesic Associates | Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same |
| US4522826A (en) * | 1984-02-08 | 1985-06-11 | Richardson-Vicks Inc. | Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same |
| US4552899A (en) * | 1984-04-09 | 1985-11-12 | Analgesic Associates | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs |
| IT1199619B (it) * | 1985-01-03 | 1988-12-30 | Oece Ind Chimiche Spa | Vernici additivate |
| FR2613225B2 (fr) * | 1986-05-16 | 1989-10-27 | Grenet Edouard | Association d'huiles essentielles et de medicaments pour les voies respiratoires, et applications de cette association en tant qu'agent de protection des voies respiratoires, en presence de fumees et de gaz nocifs pour celles-ci, provenant notamment de la combustion d'hydrocarbures et du tabac |
-
1990
- 1990-09-28 US US07/590,646 patent/US5175152A/en not_active Expired - Fee Related
-
1991
- 1991-09-25 TW TW080107546A patent/TW215418B/zh active
- 1991-09-26 WO PCT/US1991/007013 patent/WO1992005781A1/en active Application Filing
- 1991-09-26 PT PT99086A patent/PT99086A/pt not_active Application Discontinuation
- 1991-09-26 JP JP3517007A patent/JPH06501013A/ja active Pending
- 1991-09-26 AU AU87339/91A patent/AU8733991A/en not_active Abandoned
- 1991-09-27 NZ NZ239980A patent/NZ239980A/en unknown
- 1991-09-27 IE IE340591A patent/IE913405A1/en unknown
- 1991-09-28 CN CN91110643A patent/CN1060962A/zh active Pending
- 1991-09-28 MY MYPI91001772A patent/MY108564A/en unknown
- 1991-09-30 MX MX9101377A patent/MX9101377A/es not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| MX9101377A (es) | 1992-05-04 |
| IE913405A1 (en) | 1992-04-08 |
| NZ239980A (en) | 1996-10-28 |
| WO1992005781A1 (en) | 1992-04-16 |
| MY108564A (en) | 1996-10-31 |
| TW215418B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1993-11-01 |
| US5175152A (en) | 1992-12-29 |
| CN1060962A (zh) | 1992-05-13 |
| AU8733991A (en) | 1992-04-28 |
| JPH06501013A (ja) | 1994-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT99086A (pt) | Processo para a preparacao de uma composicao contendo base efedrina e salicilato de alquilo para a libertacao da base efedrina sob a forma de vapor | |
| RU2153338C2 (ru) | Никотинсодержащая таблетка и способ лечения от курения | |
| KR100511730B1 (ko) | 활성성분의 개선된 전달성을 갖는 조성물 | |
| Choudry et al. | Separation of cough and reflex bronchoconstriction by inhaled local anaesthetics | |
| US20070160689A1 (en) | Compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction | |
| ES2596262T3 (es) | Derivados de 1-amino-alquilciclohexano para su uso en el tratamiento de tinnitus asociado con pérdida de audición | |
| JP2004196821A (ja) | ベータ−２−気管支拡張薬の改善使用 | |
| JP2008019281A6 (ja) | ベータ−２−気管支拡張薬の改善使用 | |
| US5496537A (en) | Propofol hydrofluorocarbon propellant formulations | |
| EP1663112A2 (en) | Intranasal opioid compositions | |
| EP2429521A2 (en) | Sublingual dexmedetomidine compositions and methods of use thereof | |
| BR112020023741A2 (pt) | filme, métodos de tratamento de condições em pacientes humanos e de fabricação de filmes e uso de filme | |
| Pearman | Cocaine: a review | |
| US20060148837A1 (en) | Compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction | |
| PT3119201T (pt) | Soluções de sildenafilo e métodos de as preparar e utilizar | |
| WO2014113638A1 (en) | Multi-use albuterol maintenance therapy formulations and devices therefor | |
| WO2009047779A2 (en) | Composition containing fentanyl base aromatic oils and alkyl salicylate for the delivery of fentanyl base in vapour form | |
| CN102512676A (zh) | 使用噻唑衍生物的方法 | |
| WO2008062453A2 (en) | Composition containing nicotine base aromatic oils and alkyl salicylate for the delivery of nicotine base in vapour form | |
| Ullman et al. | Formoterol inhaled as dry powder or via pressurized metered‐dose inhaler in a cumulative dose‐response study | |
| ES2232769T3 (es) | Composicion farmaceutica que comprende salmeterol y budesonida para el tratamiento de trastornos respiratorios. | |
| WO2006030221A1 (en) | Pharmaceutical composition comprising a betaminetic agent and a mucolytic agent | |
| Bierman | Adrenergic drugs | |
| JPH09286735A (ja) | 内服液剤 | |
| CA2017923A1 (en) | Heated oral antitussive compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BB1A | Laying open of patent application |
Effective date: 19920407 |
|
| FC3A | Refusal |
Effective date: 19981124 |